These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25438460)

  • 21. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
    Sjöwall C; Hjorth M; Eriksson P
    Lupus; 2017 Oct; 26(12):1333-1338. PubMed ID: 28162031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):42-58. PubMed ID: 23266125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis.
    Falgàs N; Sola-Valls N; Sepúlveda M; Lapuma D; Ariño H; Llufriu S; Espinosa G; Saiz A
    Lupus; 2014 Dec; 23(14):1555-6. PubMed ID: 25107937
    [No Abstract]   [Full Text] [Related]  

  • 25. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab.
    Fredericks CA; Kvam KA; Bear J; Crabtree GS; Josephson SA
    Lupus; 2014 Jun; 23(7):711-3. PubMed ID: 24531080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-induced systemic lupus erythematosus and TNF-alpha blockers.
    Mohan AK; Edwards ET; Coté TR; Siegel JN; Braun MM
    Lancet; 2002 Aug; 360(9333):646. PubMed ID: 12241965
    [No Abstract]   [Full Text] [Related]  

  • 28. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus following methylprednisolone: report of two cases.
    Chennareddy S; Adapa R; Kishore BK; Rajasekhar L
    Int J Rheum Dis; 2013 Dec; 16(6):786-8. PubMed ID: 24131800
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
    Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
    Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Belimumab. No tangible efficacy but a risk of immunosuppression.
    Prescrire Int; 2013 Jun; 22(139):149. PubMed ID: 23866349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic lupus erythematosus. Diagnosis and treatment.
    Pisetsky DS; Gilkeson G; St Clair EW
    Med Clin North Am; 1997 Jan; 81(1):113-28. PubMed ID: 9012757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of belimumab for the treatment of systemic lupus erythematosus.
    Wise LM; Stohl W
    Expert Opin Drug Saf; 2019 Dec; 18(12):1133-1144. PubMed ID: 31657965
    [No Abstract]   [Full Text] [Related]  

  • 34. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN; Liu CS; Tsai TR; Hung YC; Chang SJ; Lin HL; Chen YC; Lai HM; Yu SF; Chen CJ
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANA negative SLE male patient with predominant pulmonary involvement.
    Shaikh YA
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):239. PubMed ID: 16542614
    [No Abstract]   [Full Text] [Related]  

  • 36. New drugs in systemic lupus erythematosus: when to start and when to stop.
    Mosca M; van Vollenhoven R
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S82-5. PubMed ID: 24129144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
    Ramachandran S; Parks D; Kurtinecz M; Roth DA; Alfonso-Cristancho R
    J Comp Eff Res; 2018 Jun; 7(6):581-593. PubMed ID: 29692179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute acalculous cholecystitis in juvenile systemic lupus erythematosus.
    Mendonça JA; Marques-Neto JF; Prando P; Appenzeller S
    Lupus; 2009 May; 18(6):561-3. PubMed ID: 19395459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Systemic Lupus Erythematosus (SLE) - New Classification Criteria].
    Aringer M; Dörner T
    Dtsch Med Wochenschr; 2018 Jun; 143(11):811-814. PubMed ID: 29807382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic lupus erythematosus: safe and effective management in primary care.
    Michalski JP; Kodner C
    Prim Care; 2010 Dec; 37(4):767-78, vii. PubMed ID: 21050957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.